PACIFIC: A Double-Blind, Placebo-Controlled Phase 3 Study of Durvalumab as Consolidation Therapy After Chemoradiation in Patients with Locally Advanced, Unresectable Non–Small Cell Lung Cancer

S.J. Antonia; A. Villegas; D. Daniel; D. Vincente Baz; S. Murakami; R. Hui; T. Yokoi; A. Chiappori; K.H. Lee; M. de Wit; B.C. Cho; M. Bourhaba; X. Quantin; T. Tokito; T. Mekhail; D. Planchard; H. Jiang; Y. Huang; P.A. Dennis; M. Özgüroğlu

doi:10.1016/j.ijrobp.2017.09.011

PACIFIC: A Double-Blind, Placebo-Controlled Phase 3 Study of Durvalumab as Consolidation Therapy After Chemoradiation in Patients with Locally Advanced, Unresectable Non–Small Cell Lung Cancer

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2017.09.011 ◽

2017 ◽

Vol 99 (5) ◽

pp. 1314-1315

Author(s):

S.J. Antonia ◽

A. Villegas ◽

D. Daniel ◽

D. Vincente Baz ◽

S. Murakami ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Locally Advanced ◽

Small Cell ◽

Consolidation Therapy ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

8LBA Biomarker evaluation in the randomized, double-blind, placebo-controlled, Phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally-advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)72037-3 ◽

2009 ◽

Vol 7 (3) ◽

pp. 5-6 ◽

Cited By ~ 14

Author(s):

B. Johnson ◽

V. Miller ◽

L. Amler ◽

H. Stern ◽

C. Soh ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Locally Advanced ◽

Small Cell ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iiib ◽

Biomarker Evaluation

Download Full-text

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)00099-1 ◽

2016 ◽

Vol 17 (6) ◽

pp. 822-835 ◽

Cited By ~ 192

Author(s):

Johan F Vansteenkiste ◽

Byoung Chul Cho ◽

Tonu Vanakesa ◽

Tommaso De Pas ◽

Marcin Zielinski ◽

...

Keyword(s):

Lung Cancer ◽

Adjuvant Therapy ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Cancer Immunotherapeutic

Download Full-text

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30634-5 ◽

2019 ◽

Vol 20 (12) ◽

pp. 1655-1669 ◽

Cited By ~ 67

Author(s):

Kazuhiko Nakagawa ◽

Edward B Garon ◽

Takashi Seto ◽

Makoto Nishio ◽

Santiago Ponce Aix ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Egfr Mutated

Download Full-text

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(12)70412-6 ◽

2012 ◽

Vol 13 (11) ◽

pp. 1161-1170 ◽

Cited By ~ 108

Author(s):

Siow Ming Lee ◽

Iftekhar Khan ◽

Sunil Upadhyay ◽

Conrad Lewanski ◽

Stephen Falk ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(12)70117-1 ◽

2012 ◽

Vol 13 (5) ◽

pp. 466-475 ◽

Cited By ~ 143

Author(s):

Li Zhang ◽

Shenglin Ma ◽

Xiangqun Song ◽

Baohui Han ◽

Ying Cheng ◽

...

Keyword(s):

Lung Cancer ◽

Maintenance Therapy ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Locally Advanced ◽

Small Cell ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind

Download Full-text

Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(21)00630-6 ◽

2022 ◽

Author(s):

Qing Zhou ◽

Ming Chen ◽

Ou Jiang ◽

Yi Pan ◽

Desheng Hu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Locally Advanced ◽

Small Cell ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind ◽

Multicentre Phase ◽

Unresectable Stage

Download Full-text

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(11)60545-x ◽

2011 ◽

Vol 377 (9780) ◽

pp. 1846-1854 ◽

Cited By ~ 251

Author(s):

Roy S Herbst ◽

Rafat Ansari ◽

Frederique Bustin ◽

Patrick Flynn ◽

Lowell Hart ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Line Chemotherapy

Download Full-text

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral Talactoferrin in Combination with Carboplatin and Paclitaxel in Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer

Journal of Thoracic Oncology ◽

10.1097/jto.0b013e3182156250 ◽

2011 ◽

Vol 6 (6) ◽

pp. 1098-1103 ◽

Cited By ~ 42

Author(s):

Raghunadharao Digumarti ◽

Yenyun Wang ◽

Ganapathi Raman ◽

Dinesh C. Doval ◽

Suresh H. Advani ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Phase Ii Study ◽

Locally Advanced ◽

Small Cell ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study

British Journal of Cancer ◽

10.1038/s41416-021-01356-3 ◽

2021 ◽

Author(s):

Ying Cheng ◽

Qiming Wang ◽

Kai Li ◽

Jianhua Shi ◽

Ying Liu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Phase 2 ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Download Full-text

PD6-3-6: A phase 3 randomized, double blind, placebo-controlled study of patients with previously untreated extensive-stage small cell lung cancer (SCLC) treated with platinum plus etoposide chemotherapy with or without darbepoetin alfa

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000283344.69129.a5 ◽

2007 ◽

Vol 2 (8) ◽

pp. S433-S434 ◽

Cited By ~ 2

Author(s):

Robert Pirker ◽

Rodryg Ramlau ◽

Wolfgang Schuette ◽

Petr Zatloukal ◽

Irene Ferreira ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Darbepoetin Alfa ◽

Small Cell ◽

Controlled Study ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Extensive Stage

Download Full-text